Wuxi
News
Jemincare Innovative Medicine & Biological Medicine Production Base Project Settles in Wuxi National High-tech District
Release time:2020-09-14 Browse:
 

A few days ago, Wuxi National High-tech District and Jemincare Group held a signing ceremony for the Specific Neutralizing Antibody Innovative Medicine Project & the Macromolecule Biological Medicine Production Base Project. Huang Qin, Secretary of the CPC Wuxi Municipal Committee, attended the signing ceremony. Jiang Min, Vice Mayor of Wuxi, Secretary of Party Working Committee of Wuxi National High-tech District and Secretary of CPC Wuxi New District Committee, and Li Yihai, Chairman of Jemincare Group, delivered speeches.

 

Jemincare Group is a leading large-scale modern pharmaceutical group in China. The Specific Neutralizing Antibody Innovative Medicine Project & the Macromolecule Biological Medicine Production Base Project signed this time is the third project of Jemincare Group in Wuxi National High-tech District after Wuxi Jemincare Shanhe Pharmaceutical Co., Ltd. and the biological medicine innovative technology industrialization project. It is also the first settled industrialization project after Jemincare Group enters the macromolecule biological pharmacy field.

 

With a total investment of over 1.6 billion yuan, Jemincare Group will take Wuxi National High-tech District as the macromolecule biological medicine R&D and production headquarters after the completion of the signed project. It will have collaborative innovation and in-depth cooperation in R&D and production with the current Shanghai Jemincare Zhangjiang Research Institute and Wuxi Jemincare Shanhe Pharmaceutical Co., Ltd. and form a full industrial chain layout integrating macromolecule medicine R&D and large-scale commercial production.

 

All rights reserved Sponsored by Wuxi Municipal People's Government Office

Technical Support: Wuxi WangDao  Network Support: Wuxi Mobile  Security Support: Jiangsu Jun'an Detection